Genocea Biosciences Inc. (NASDAQ:GNCA) saw unusually-high trading volume on Monday . Approximately 325,069 shares traded hands during mid-day trading, an increase of 31% from the previous session’s volume of 249,095 shares.The stock last traded at $5.26 and had previously closed at $5.03.

GNCA has been the subject of a number of research reports. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research report on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Genocea Biosciences presently has a consensus rating of “Buy” and a consensus target price of $17.95.

The stock has a 50 day moving average of $4.36 and a 200-day moving average of $4.35. The stock’s market cap is $150.45 million.

Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.05. On average, equities analysts anticipate that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.